Summary
Differentiation therapy is an approach that utilizes our understanding of the hierarchy of cellular systems to pharmacologically induce a shift towards terminal commitment. While this approach has been a paradigm in treating certain hematological malignancies, efforts to translate this success to solid tumors have proven challenging. In this study we show that activation of PKA drives aberrant mammary differentiation by diminishing the self-renewing potential of the basal compartment. PKA activation results in tumors that are more benign, exhibiting reduced metastatic propensity, loss of tumor-initiating potential and increased sensitivity to chemotherapy. Analysis of tumor histopathology revealed features of overt differentiation with papillary characteristics. Longitudinal single cell profiling at the hyperplasia and tumor stages uncovered an altered path of tumor evolution whereby PKA curtails the emergence of aggressive subpopulations. PKA activation represents a promising approach as an adjuvant to chemotherapy for certain breast cancers, reviving the paradigm of differentiation therapy for solid tumors.